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Abstract
Introduction: The aim of the study was to assess the influence of non-small cell lung cancer chemotherapy on patients’ health 
status, the occurrence of adverse events and their effect on everyday activities, depending on the patients’ sex and age.
Material and methods: The study group consisted of 62 non-small cell lung cancer patients, (21 women and 41 men), aged 
51–84 years, hospitalised due to the chemotherapy. The survey included SF-20 test and a questionnaire prepared by the authors. 
Results: The most frequent adverse events indicated by the patients were: weakness (79%), nausea and vomiting (77%), loss of 
appetite (56%) and diarrhoea (45%). It was found that the side-effects of chemotherapy were not dependent on age (p = 0.9882) 
or sex (p = 0.9968).
The chemotherapy negatively influenced the quality of the patients’ life (p < 0.000001). It was shown that there is a statistically 
significant correlation between age and limitations on social roles, professional life and performing housework (p < 0.0133), and 
also the inability to perform specific types of activities (p < 0.01). 
Conclusions: The results of the study show that chemotherapy of non-small cell lung cancer was connected with decreased 
quality of life, especially in patients over 65 years of age. The patients under 65 years of age could not deal with the disease in 
respect of psychological aspects, whereas people over 65 years of age had greater problems with physical, social and profes-
sional functioning.
Key words: chemotherapy, quality of life, non-small cell lung cancer, adverse events
Pneumonol. Alergol. Pol. 2014; 82: 349–357 
Streszczenie 
Wstęp: Celem pracy była ocena jakości życia chorych na niedrobnokomórkowego raka płuca (z uwzględnieniem wieku i płci) 
poddanym leczeniu cytostatycznemu. 
Materiał i metody: Badanie przeprowadzono u 62 chorych (21 kobiet i 41 mężczyzn) w wieku 51–84 lata hospitalizowanych celem 
chemioterapii niedrobnokomórkowego raka płuca. W badaniach wykorzystano test SF-20 oraz ankietę własnego autorstwa. 
Wyniki: Do najczęstszych objawów niepożądanych chemioterapii wskazywanych przez chorych należało osłabienie (79%), nud-
ności i wymioty (77%), utrata apetytu (56%), oraz biegunka (45%). Stwierdzono, że działania niepożądane w trakcie chemioterapii 
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nie były zależne od wieku (p = 0,9882) i płci (p = 0,9968). Badając wpływ liczby podanych kursów chemioterapii na ocenę 
własnego zdrowia, stwierdzono, że im mniej kursów chemioterapii otrzymali pacjenci, tym lepiej oceniali swoją jakość życia 
(p <  0,000001). Wykazano istotną statystycznie zależność między wiekiem chorych a  ograniczeniami: w  pełnieniu ról spo-
łecznych, w podejmowaniu pracy zawodowej oraz w wykonywaniu prac domowych (p < 0,0133), a także pomiędzy wiekiem 
a niezdolnością do wykonania pewnego rodzaju pracy lub pewnej ilości zajęć domowych (p < 0,01). 
Wnioski: Chemioterapia niedrobnokomórkowego raka płuca w znacznie większym stopniu ograniczała jakość życia chorych po 
65. roku życia, w porównaniu z pozostałymi. Stwierdzono, że chorzy poniżej 65. roku życia gorzej radzili sobie z chorobą w aspek-
cie psychologicznym, natomiast chorzy po 65. roku życia mieli większe problemy z  funkcjonowaniem fizycznym, społecznym 
i zawodowym. 
Słowa kluczowe: chemioterapia, jakość życia, niedrobnokomórkowy rak płuca, objawy niepożądane 
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Introduction
Epidemiological data
Due to its high prevalence, lung cancer is 
placed among the most frequent malignant neo-
plasms [1]. It represents annually approximately 
21% of all diagnosed cancers in men and about 
8.5% in women. Poland is one of the countries 
with the highest incidence and mortality rates 
of lung cancer. The standardised incidence rate 
in 2010 amounted to 52.2/100,000 for men and 
16.9/100,000 for women. The incidence rate 
of lung cancer is closely related to age. Peak 
incidence occurs between 60 and 64 years of 
age both in men and women, but recently, more 
frequently than in previous years, the disease is 
being diagnosed in young people, 40-50 years 
of age. In 2010, standardised mortality rates in 
Poland amounted to 56.2/100,000 for men and 
16.3/100,000 for women [2]. 
Prognosis in lung cancer is poor. In Poland, 
the percentages of 1- and 5-year survival are 
among the lowest in Europe, which undoubtedly 
is the effect of late diagnosis of the disease [3]. 
The results of the EUROCARE-4 study show that 
the percentage of a 5-year survivors in Poland is 
11.59% for men and 14.16% for women, whereas 
1-year survival is 35.62% for men and 37.85% for 
women [4]. 
Quality of life during chemotherapy
Quality of life is an elusive concept as it de-
pends on the philosophy of life, education and 
tradition. It is easier to talk about its elements, 
and finally, it is thought that the quality of life 
can be defined as the judgement of a personal 
situation, concerning a certain period of time [5].
Traditional criteria for the assessment of the 
results of treatment of cancer include complete 
survival time, time to progression and toxicity rate 
concerning cytotoxic treatment. Recently, special 
attention has been paid to the quality of life of 
oncological patients. It is caused by the fact that 
treatment results, particularly in relation to lung 
cancer patients, are still not satisfactory. Many 
studies have shown that making a life longer by 
a  few months is an unsatisfactory index of the 
efficacy of treatment. The success of treatment 
should be defined by two factors: the prolongation 
of life and maintaining its good quality. 
Quality of life is always a subjective value, 
and to a large extent it depends on mental state, 
personal qualities, taste, and the system of values 
of a given person [6].
The patient and his/her family usually 
associate neoplastic disease with death. The 
disease causes great mental stress, even if it 
does not lead to physical suffering or does not 
limit physical or social activity. It is the result 
of the specificity of the disease and is associa-
ted with emotions such as anger, sadness and 
annoyance. According to patients, the most 
bothersome symptoms are vomiting and loss of 
hair, followed by sleepiness, fatigue, pain, loss 
of appetite and lowered life satisfaction [5]. 
Cancer pain is chronic and it often represents 
the biggest problem to the patient. Long-lasting 
pain results in depression, anxiety and physical 
exhaustion. Another symptom that disturbs the 
quality of life is the anxiety about the possible 
loss of a certain value. 
In cancer, suffering rarely passes; on the con-
trary, it often becomes more intensive with time. 
It negatively influences almost every area of life. 
Physical fitness and mental state are lowered, and 
opposing emotions may occur alternately, e.g. 
low spirits, sensitivity, aggression, anxiety, in-
difference, emotional dependence. Patients often 
lose their willingness, strength and motivation 
to fight the disease. It frequently means failure 
to fulfil basic needs in spite of having plenty of 
time, usually spent alone.
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The term health-related quality of life (HRQOL) 
was introduced by Schipper et al., who defined it 
as the ‘functional effect of a disease perceived by 
a patient’. The concept had numerous supporters, 
including Wołowicka and de Walden-Gałuszko 
[7]. Quality of life is evaluated using various 
questionnaires (general, mixed, specific). Among 
lung cancer patients, the following questionnaires 
are usually used:
1.  QLQ-C30 and the module for lung cancer LC-13. 
The questionnaire was drawn up by the 
European Organisation for the Research and 
Treatment of Cancer (EORTC). It is designed 
for patients to self-assess their somatic and 
mental status, social relations and physical 
fitness. It includes the QLQ-C30 core qu-
estionnaire (common for all cancers) and an 
additional module that takes into account 
specific features for a given cancer (LC-13 is 
designed for lung cancer) [8, 9]. 
2.  MOS SF-20 (Medical Outcome Study Short 
Form 20). The SF-20 test is a  shortened 
version of the SF-36. It includes 20 state-
ments gathered in 6 domains: MH — mental 
health, PF — physical functioning, HP — 
health perception, PP — pain perception, 
RF — role functioning and SF — social 
functioning [7, 10].
3.  WHOQOL-Bref. WHOQOL-Bref includes 26 
questions and concerns four areas of quality 
of life: physical, mental, social and environ-
mental [11, 12].
The aim of the study was to assess the in-
fluence of chemotherapy of non-small cell lung 
cancer on the patients’ quality of life, health 
status and on everyday activities, depending on 
the patients’ sex and age.
Material and methods
The study was conducted at the Department 
of Clinical Oncology, University of Rzeszów 
between September 2011 and January 2012. 
It enrolled 62 consecutive patients with non-small 
cell lung cancer (NSCLC) — 21 women (87%) 
and 41 men (66%), without brain metastases, 
not treated to date. The mean age was 65.5 years 
(± 8.58), range 51–84. 
The performance status was assessed accor-
ding to the Karnofsky scale and it amounted to 
80–100%, whereas clinical stage of the disease 
according to WHO was IIIB or IV. 
Arterial hypertension dominated among 
concomitant diseases (in approximately 80% of 
the patients), other diseases were: stable coronary 
heart disease, diabetes and chronic obstructive 
pulmonary disease. 
The patients mentioned the following symp-
toms: dyspnoea, strength reduction and pain, 
which was controlled with non-steroidal anti
-inflammatory drugs and weak opioids. No si-
gnificant abnormalities were found in blood cell 
count or blood smear, liver or renal parameters, 
which allowed the introduction and continuation 
of cytotoxic treatment. 
The patients received chemotherapy consi-
sting of cisplatin at a dose of 30 mg/m2 for 3 succes-
sive days, with vinorelbine at a dose of 30 mg/m2 
or with gemcitabine at a dose of 1250 mg/m2 on 
the 1st and 8th day every 21 days. Each patient re-
ceived at least one course of chemotherapy. Most 
of the patients (43/61) received 2–4 courses. Due 
to a various number of chemotherapy courses, the 
subjects were divided into three groups: patients 
who received one course of chemotherapy (9 pa-
tients — 15%), those who received 2–4 courses 
(43 patients — 69%) and those who received 5–6 
chemotherapy courses (10 patients — 16%). 
Ondansetron and dexamethasone were used 
as premedication. According to the RECIST cri-
teria, the evaluation of treatment efficacy was 
assessed every three courses. The patients from 
the study group did not undergo radiotherapy. 
A questionnaire prepared by the authors 
of the study was also used. The questionnaire 
was anonymous and it included 17 one-choice 
and multiple-choice questions that concerned 
demographic data and symptoms/suffering that 
occurred during chemotherapy. The standardised 
SF-20 test was also used. 
The patients were divided into two age gro-
ups: over 65 years of age — 34 (55.84%), and 
under 65 years of age 28 (45.16%). Statistical 
analysis consisted of proportional comparison 
of the results, according to the age and sex of the 
patients. The chi-square test was applied in order 
to check the differences in variables measured in 
the study groups. P < 0.05 was considered signi-
ficant. Only the results that achieved statistical 
significance in the SF-20 test have been presented 
in the study.
Results
Most of the patients were scared of treatment 
(74.19%), 62.9% of them were afraid of the effects 
of the disease and 43.55% of the respondents 
experienced low spirits (Fig. 1).
Table 1 presents the opinion of the pa-
tients concerning their quality of life during 
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Table 1. Quality of life of lung cancer patients depending on the number of chemotherapy courses 
How do you assess your health during chemotherapy? Total number  
of patients
Number  
of courses
Very bad Bad Neither good  
nor bad
Good
n % n % n % n % n %
1 0 0 0 0  0  0  9 100  9 100
p < 0.000001
2–4 0 0 7 16 24 56 12  28 43 100
5–6 1 10 9  90  0  0  0  0 10 100
Total 1 10 16 26 24 39 21 34 62 100.00
Figure 1. Psychological adverse events associated with treatment
Table 2. The relationship between age and the incidence of adverse events caused by chemotherapy
Have you experienced during chemotherapy? Age bracket
≤ 65 years of age
No 28
> 65 years of age
No 34
n % n %
Weakness 19 68 30 88
p = 0.9882
Nausea and vomiting 19 68 29 85
Inflammation of the mucous membrane 19 68 26 76
Loss of appetite 14 50 21 62
Diarrhoea 13 46 15 44
Hair loss 19 68 25 74
chemotherapy, depending on the number of 
chemotherapy courses used. All of the patients 
who received only one course of chemotherapy 
evaluated their health status as good, whereas 
9/10 patients who received 5–6 courses assessed 
it as bad. It was observed that a lower number 
of chemotherapy courses was combined with 
better quality of the patients’ lives, mainly due 
to less pronounced side effects during systemic 
treatment. 
The patients most frequently reported the 
following adverse effects of treatment: weakness 
(79%), nausea and vomiting (77%), hair loss 
(71%), inflammation of the mucous membranes 
(73%) and less frequently — diarrhoea (45%). 
Furthermore, it was found that 76% of the pa-
tients had sleep problems that had not been 
observed prior to chemotherapy. Adverse events 
that occurred during chemotherapy did not 
depend on age (p = 0.9882) or sex (p = 0.9968) 
(Tables 2, 3).
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Table 3. The relationship between sex and the incidence of adverse events caused by chemotherapy
Have you experienced during  
chemotherapy?
Sex
Women
No 21
Men
No 41
n % n %
Weakness 16 76 33 80
p = 0.9968
Nausea and vomiting 17 81 31 76
Inflammation of the mucous membrane 15 71 30 73
Loss of appetite 11 52 24 59
Diarrhoea 10 48 18 44
Hair loss 16  76 28 68
Table 4. Mental health (MH) status according to patients’ age
 Age Significance 
level p
 ≤ 65 years of age
No 28
> 65 years of age
No 34
n % n %
For how long during the last month were 
you depressed and in low spirits? (MH3)
All of the time 10 35 1 3
0.0026
Most of the time 9 32 5 15
Quite a lot of the time 4 14 14 41
For some time 3 11 7 21
For a short time 2 7 6 18
Not at all 0 0 1 3
 How often during the last month were 
you so depressed that there was nothing 
that could cheer you up? (MH5)
All of the time 11 39 3 9
0.0256
Most of the time 9 32 8 24
Quite a lot of the time 3 11 4 12
 For some time 3 11 9 26
 For a short time 2 7 9 26
 Not at all 0 0 1 3
The analysis of the SF-20 test
Scale I — Mental Health (MH)
The conducted analysis showed that sex had 
no impact on mental or physical health, health 
perception, or social functioning of the study 
patients; therefore, data concerning this aspect 
were not presented in the study. However, there 
was a  statistically significant correlation be-
tween age and depression (Table 4). The patients 
under 65 years of age more frequently reported 
low spirits (35%) and that there was nothing 
that could cheer them up (39%) compared to 
the patients above 65 years of age (3% and 9%, 
respectively). 
Scale II — Physical Functioning (PF)
The conducted analysis showed the impact of 
age on some activities. Limitations lasting more 
than 3 months were observed more frequently 
in the patients over 65 years of age. Statistical 
dependence was found between age and the per-
formance of activities such as standing up, going 
up the third or higher floor (p < 0.02), bending 
forward or lifting objects (p < 0.0256), and every-
day activities, e.g. eating, getting dressed, taking 
a bath or using the toilet (p < 0.068) (Table 5).
Scale III — Health perception (HP)
Age played a crucial role in health percep-
tion (Table 6). There was a statistical correlation 
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Table 5. Physical functioning (PF) according to patients’ age
Age Significance 
level p
≤ 65 years of age
No 28
> 65 years of age
No 34
n % n %
Standing up or going up the stairs (PF1) Limitations for over 3 months 14 50 27 79
0.0200Limitations up to 3 months 14 50 6 18
No limitations 0 0 1 3
Bending forward, lifting objects or bending 
down (PF2)
Limitations for over 3 months 11 39 23 68
0.0256Limitations up to 3 months 9 32 9 26
No limitations 8 29 2 6
Eating, getting dressed, bathing or using 
the toilet (PF3)
Limitations for over 3 months 3 11 10 29
0.0680Limitations up to 3 months 15  54 19 56
No limitations 10  35 5 15
Table 6. Health perception (HP) according to patients’ age
 Age  Significance 
level p
≤ 65 years of age
No 28
> 65 years of age
No 34
n % n %
Would you say that your health is: (HP1) Perfect 0 0 1 3
0.0001
Very good 0 0 1 3
Good 16 57 3 9
Medium 9 32 10 29
Rather poor 3 11 19 56
I am as healthy as anyone else (HP2) All of the time 1 4 0 0
0.0019
 Most of the time 9 32 0 0
A lot of the time 4 14 3 9
For some of the time 6 21 7 21
For a short time 5 18 9 26
Not at all 3 11 15 44
Recently I have felt bad (HP3) All of the time 0 0 9 26
0.0006
Most of the time 2 7 9 26
A lot of the time 7 25 10 29
For some of the time 8 29 4 12
For a short time 9 32 2 6
Not at all 2 7 0 0
between the patients’ age and general self-assess-
ment of their health (p < 0.0001). 19/34 (56%) of 
patients over 65 years of age assessed their health 
as rather poor, compared to 3/28 (11%) of patients 
under 65 years of age. It means that the patients 
under 65 years of age were more optimistic about 
their health status. 
The influence of age on health perception 
(“I  am healthy as no one else”) was observed 
(p < 0.0019). Among the study subjects, 32% of 
the patients under 65 years of age assessed that 
they felt healthy for most of the time, and only 
11% did not feel healthy at all. Whereas among the 
patients over 65 years of age, none felt healthy for 
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Table 7. Role functioning (RF) according to patients’ age
Age Significance 
level p
≤ 65 years of age
No 28
> 65 years of age
No 34
n % n %
Does your health status prevent you from 
taking up a job or doing the housework (ina-
bility to take up a job and to do the house-
work)? (RF1)
Limitations for over 3 months 10 35 19 56
0.0133Limitations up to 3 months 12 42 15 44
 No limitations 6  21 0  0
Were you unable to do certain types of work 
or amount of work or the housework (RF2)
 Limitations for over 3 months 6  21 20 59
0.01
Limitations up to 3 months 22 79 14 41
Table 8. Social functioning (SF) according to patients’ age 
 Age Significance 
level p
≤ 65 years of age
No 28
> 65 years of age
No 34
n % n %
How often during the last month have you 
limited your social life due to your health 
(e.g. visiting friends, relatives,  
neighbours)? (SF)
All of the time 1 4 14 41
0.0049
Most of the time 3 11 7 21
A lot of the time 4 14 2 6
For some of the time 6 21 5 15
For a short time 7 25 4 12
Not at all 7 25 2 6
most of the time and 44% did not feel healthy at 
all. 26% of younger patients declared that most of 
time recently they had felt bad, compared to 7% of 
the patients from the younger group (p < 0.0006).
Scale IV — Role functioning (RF)
46.78% of the respondents worked less due 
to their health condition, whereas 43.54% of the 
patients thought that disease restricted their lives 
to a  certain degree. 9.68% of the respondents 
reported that they were not limited in any way 
and could work or do the housework.
The influence of age on ceasing (p < 0.01) and 
on restricting (p < 0.0133) professional activity 
and housework was found (Table 7). 59% of the 
respondents over 65 years of age answered that 
chemotherapy had markedly limited their pro-
fessional functioning and domestic activities for 
over three months. The same problem concerned 
just 21% of the respondents under 65 years of age.
Scale V — Social Functioning (SF)
The health status of the patients over 65 
years of age limited their social lives to a greater 
degree, compared to younger patients (Table 8). 
41% of the patients over 65 years of age had li-
mited their social relations during the previous 
month, comparing to 4% of younger patients (p < 
0.0049). However, age itself, not only the disease, 
may also impact social relations. 
Discussion
 Research concerning quality of life during 
chemotherapy of patients with diagnosed lung 
cancer is of vital importance, as it allows us to 
recognise their expectations of therapy and to 
assess all aspects of the patient’s functioning in 
different areas of life. According to some studies, 
chemotherapy causes many adverse effects on 
quality of life [13–15]. The analysis of the results 
concerning the relation of chemotherapy courses 
and self-assessment of health status by the pa-
tients showed that all the subjects who received 
only one course of chemotherapy evaluated their 
health as good, whereas 100% of the patients who 
received 5–6 chemotherapy courses assessed their 
health status as bad or very bad. According to the 
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present study, there was a statistically significant 
dependence (p < 0.000001) between the num-
ber of administered chemotherapy courses and 
self-assessment of health. The fewer chemothera-
py courses were given, the better was the patients’ 
quality of life. This fact may be caused by adverse 
events during systemic treatment and also by the 
necessity of staying in hospital. The literature 
does not provide data concerning the relation 
between patients’ self-assessment of health and 
the number of given chemotherapy courses in the 
therapy of NSCLC. The impact of chemotherapy 
on the quality of patients’ lives is still being inve-
stigated. The aim of chemotherapy in stages III 
and IV is to decrease the tumour mass, to reduce 
suffering associated with cancer and to improve 
the quality of life after regression of adverse 
events of chemiotherapy. For most of the patients, 
chemotherapy was combined with greater stress 
than the lung cancer itself [16]. According to 
other research projects, patients who received 
chemotherapy were satisfied with their general 
quality of life. Butler et al. have shown that the 
evaluation of quality of life is an important ele-
ment in overall assessment of a patient’s health. 
They maintain that chemotherapy may improve 
the patient’s quality of life due to regression of 
ailments associated with the tumour mass [17].
Diagnosis of neoplastic disease often triggers 
negative emotions in patients, and in addition, the 
treatment causes adverse events [18]. According 
to the literature, at the moment of diagnosis, most 
patients are afraid of therapy and the effects of 
the disease. According to data from the literature, 
anxiety, fear of disease and depression occur in 
approximately 80% of patients [19]. 
Many patients treated with chemotherapy 
due to lung cancer suffer from weakness, espe-
cially during prolonged therapy. According to 
Zielińska-Więczkowska et al., patients who un-
derwent chemotherapy complained mostly of 
fatigue, weakness and sleep problems [20]. In 
the present study, the most frequent problem was 
weakness (79%). Another frequent difficulty that 
occurred during chemotherapy in our group of 
patients were gastro-intestinal symptoms (nausea 
and vomiting — 77%). According to the literatu-
re, nausea and vomiting occur in approximately 
50–60% of lung cancer patients, and more often 
among women [21]. Słowik-Gabryelska et al. [21] 
and Kruk et al. [22] showed that the intensity of 
gastro-intestinal symptoms depends on patients’ 
age, drug dosage and the effects of therapy. 
Other frequent adverse events in our group 
of patients were hair loss (71%) and sleep pro-
blems (76%). Chwiałkowski et al. showed that 
the most frequent complication of chemotherapy 
was hair loss, which occurred in 100% of pa-
tients, whereas sleeping problems were sparse 
(27%) [19].
While assessing the mental health of the stu-
dy subjects (SF-20 test), it was found that during 
chemotherapy most of the patients were nervous, 
depressed and in low spirits.
According to the conducted analysis, age 
partially influenced the mental health of the study 
subjects. Statistically significant differences were 
found between older and younger patients concer-
ning the occurrence of the feeling of depression 
and low spirits (p < 0.0026). The analysis of the 
obtained data of the SF-20 test showed that che-
motherapy, to a considerable degree, influenced 
the patients’ functioning in everyday life. It was 
observed that in 35% of the patients under 65 
years of age no limitations on everyday activities 
occurred, compared to 15% of patients over 65 
years of age (p < 0.0680). In Leppert’s study, 
problems with everyday activities occurred rarely 
and appeared in 13.4% of the patients [23]. It was 
assessed that activities that need some muscle 
strength, such as standing up, bending forward 
and walking without rest, were significantly di-
sturbed during chemotherapy. 
In the opinion of Słowik-Gabryelska et al., 
lung cancer patients are particularly at risk 
of adverse events during chemotherapy. They 
showed that in more than half of the patients, 
adverse events lowered general functioning and 
negatively influenced their quality of life [24].
In the present study, a significant dependence 
was found between the patients’ age and general 
health perception (p < 0.0001). The patients 
over 65 years of age felt significantly worse and 
evaluated their health negatively. No dominating 
concomitant diseases were found in this group. 
The patients under 65 years of age evaluated their 
health more optimistically and felt better. 
The disease markedly restricted the patients’ 
role functioning. 46.8% of the subjects had their 
professional and domestic functioning limited for 
over three months. Just 6/62 patients (9.6%) could 
work professionally or do the housework without 
any limitations. A statistically significant corre-
lation was found between age and limitations on 
social and professional functioning. The patients 
over 65 years of age had greater difficulties with 
maintaining professional and home activity than 
did the younger ones (p < 0.01). 
The present study showed that the patients 
markedly limited their social life due to their 
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health condition and chemotherapy. Nevertheless, 
this concerned only 4% of patients under 65 years 
of age and 41% of patients above 65 years of age. 
The present study concerning the quality of 
life of the patients hospitalised due to chemothe-
rapy showed that the disease and the therapy 
significantly deteriorated their quality of life. 
There is a need for further research to evaluate 
the quality of life after completed chemotherapy, 
based on the efficacy of applied treatment.
Conclusions
The adverse events that occurred in the pa-
tients treated with chemotherapy did not depend 
on age or sex.
It was found that, in the course of cytotoxic 
treatment, the smaller the number of chemothera-
py courses, the better the patients’ quality of life, 
which was associated with less intensive adverse 
effects of chemotherapy. 
The study showed (based on the results of 
the SF-20 test) that mental health was impaired 
more frequently in the patients below 65 years of 
age than in the older ones, but limitation of daily 
activities, social functioning and self-perception 
of health status were significantly greater in the 
patients over 65 years of age compared to the 
younger ones. 
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